Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
复制标题
DOI：
10.1016/j.ijrobp.2005.05.034
复制
发表时间：
2005-12-01
影响因子：
7
通讯作者：
Hiraoka, M
中科院分区：
文献类型：
--
作者：
Nagata, Y;Takayama, K;Hiraoka, M
目的：为了评估48戈伊的三维立体定向放射治疗在四个部分治疗I期肺癌使用立体定向body frame.Methods和材料的临床结局：45例患者之间治疗1998年9月和2004年2月被列入本研究。32名患者患有IA期肺癌，另外13名患者患有IB期肺癌，其中肿瘤直径小于4 cm。采用6-10个非共面射束进行三维治疗计划，以保持靶区剂量均匀性，并减少照射肺体积> 20戈伊。所有患者均采用立体定向体框照射，并在等中心接受4次单次12戈伊高剂量照射，照射时间为5-13（中位数= 12）day.Results：7例（16%）肿瘤在治疗后完全消失（CR），38例（84%）肿瘤体积缩小30%或更多（PR）。因此，所有肿瘤均显示局部缓解。在6-71（中位数= 30）个月的随访期间，没有发现大于国家癌症研究所常见毒性标准3级的肺部并发症。未发生其他血管、心脏、食管或神经系统毒性。45例肿瘤中有44例（98%）在随访期间得到局部控制。然而，区域复发和远处转移分别发生在3和5的T1患者和0和4的T2患者。对于IA期肺癌，1年和3年后的无病生存率和总生存率分别为80%和72%，92%和83%，而对于113期肺癌，无病生存率和总生存率分别为92%和71%，82%和72%。48戈伊的3D立体定向放射治疗分4次使用立体定向体架是有用的治疗I期肺肿瘤。(c)2005年爱思唯尔公司
Purpose: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic body frame.Methods and Materials: Forty-five patients who were treated between September 1998 and February 2004 were included in this study. Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 6-10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume > 20 Gy. All patients were irradiated using a stereotactic body frame and received four single 12 Gy high doses of radiation at the isocenter over 5-13 (median = 12) days.Results: Seven tumors (16%) completely disappeared after treatment (CR) and 38 tumors (84%) decreased in size by 30% or more (PR). Therefore, all tumors showed local response. During the follow-up of 6-71 (median = 30) months, no pulmonary complications greater than an National Cancer Institute-Common Toxicity Criteria of Grade 3 were noted. No other vascular, cardiac, esophageal, or neurologic toxicities were encountered. Forty-four (98%) of 45 tumors were locally controlled during the follow-up period. However, regional recurrences and distant metastases occurred in 3 and 5 of T1 patients and zero and 4 of T2 patients, respectively. For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage 113 lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively.Conclusion: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic body frame is useful for the treatment of Stage I lung tumors. (c) 2005 Elsevier Inc.